Celanese Q2 adjusted EPS beats estimates, sales meet expectations

Overview

• US chemical materials maker's Q2 sales met analyst expectations, rising 18% sequentially

• Adjusted EPS for Q2 beat analyst expectations

• Company completed cost-saving initiatives expected to deliver over $50 mln in annualized savings

Outlook

• Celanese expects Q3 adjusted EPS of about $1.35 to $1.75

• Company maintains full-year adjusted EPS guidance of about $6.00

• Celanese expects 2026 free cash flow of $700 mln to $800 mln

Result Drivers

• PRICE AND VOLUME GAINS - Co said Q2 sales rose on higher prices and increased volumes across both business segments

• GROWTH PLATFORMS - Co cited continued momentum in medical and electronics as contributing to results

• COST SAVINGS INITIATIVES - Facility closures and manufacturing network optimization expected to deliver over $50 mln in annualized fixed-cost savings

Company press release: ID:nBw4BgJqma

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the specialty chemicals peer group is "buy"

• Wall Street's median 12-month price target for Celanese Corp is $68.00, about 54.9% above its August 3 closing price of $43.89

• The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 12 three months ago

Reuters Recommended Reads

• Aug 4 - DuPont narrows annual sales forecast on water business weakness, shares down

• Aug 4 - Westlake Chemical Partners' Q2 net income dips

• Aug 4 - Synthomer shares jump as UK specialty chemicals firm lifts 2026 outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)